Granules India net profit rises 39% to ₹182 cr on higher revenue
Revenue crosses ₹1,500 crore despite higher input and logistics costs driven by West Asia tensions, expect cost pressures to persist, says CMD Chigurupati
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more.
Unlock these with Subscription
The View From India Looking at World Affairs from the Indian perspective.
First Day First Show News and reviews from the world of cinema and streaming.
Today's Cache Your download of the top 5 technology stories of the day.
Science For All The weekly newsletter from science writers takes the jargon out of science and puts the fun in!
Data Point Decoding the headlines with facts, figures, and numbers
THEdge At the cutting edge of education and careers
Health Matters Ramya Kannan writes to you on getting to good health, and staying there
Gender Agenda Stories from beyond the binary.
The Hindu On Books Books of the week, reviews, excerpts, new titles and features.
Published - November 02, 2026 07:15 pm IST - HYDERABAD
Granules is well positioned in its transition towards complex generics and peptide CDMO. | Photo Credit: The Hindu
Drugmaker Granules India reported 39% year-on-year (YoY) jump in consolidated net profit to ₹181.8 crore in September quarter.
The profit came on a 20% YoY increase in revenue from operations to ₹1,559.9 crore.
Sequentially, however, the growth was subdued.
Granules had posted ₹179.9 crore net profit and ₹1,476.7 crore revenue from operations in the June quarter.
“Our quarterly revenue has crossed ₹1,500 crore in Q2 FY27 with EBITDA of ₹338 crore despite higher input and logistics costs from tensions in West Asia,” said Krishna Prasad Chigurupati, chairman and managing director.
The cost pressures are expected to persist and the company will work with customers to manage them with a lag, he said.
Mr.Chigurupati sought to highlight Granules is well positioned in its transition towards complex generics and peptide CDMO.
The company backed by ₹828 crore net cash plans to invest in research and development, manufacturing and quality.
On the recent U.S.
FDA inspection of the company’s finished dosage facility in Gagillapur, Hyderabad, he said the inspection progressed constructively.
The management believes the observations can be addressed through responses as well as corrective and preventive actions.
The regulator had issued 11 observations post the inspection.
On Monday, Granules shares closed 2.38% at ₹819.55 apiece on the BSE.
business (general) / pharmaceutical / generic drugs / earnings / earnings forecast / company information / inflation and deflation
Terms & conditions | Institutional Subscriber
Comments have to be in English, and in full sentences.
They cannot be abusive or personal.
Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform.
If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles.
If you do not have an account please register and login to post comments.
Users can access their older comments by logging into their accounts on Vuukle.
Full detailed coverage is shown on the council website above. Source attribution: The Hindu – Business.
Back to all council news
